Shopping Cart
- Remove All
- Your shopping cart is currently empty
IRAK4-IN-27 (Compound 22) is a potent and selective IRAK4 inhibitor with an IC50 of 8.7 nM. It effectively suppresses cell growth and induces apoptosis in the MYD88 L265P diffuse large B-cell lymphoma (DLBCL) cell line, making it a valuable agent for DLBCL research [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | IRAK4-IN-27 (Compound 22) is a potent and selective IRAK4 inhibitor with an IC50 of 8.7 nM. It effectively suppresses cell growth and induces apoptosis in the MYD88 L265P diffuse large B-cell lymphoma (DLBCL) cell line, making it a valuable agent for DLBCL research [1]. |
Targets&IC50 | IRAK4:8.7 nM |
In vitro | IRAK4-IN-27 (Compound 22, 72 h) exhibited antiproliferative activity in MYD88 L265P DLBCL cell lines (OCI-LY10, IC50 = 0.248 μM) and MYD88 wild-type cell lines (U2932, IC50 = 1.251 μM; GM00637, IC50 = 1.520 μM). IRAK4-IN-27 (0.5 μM and 1 μM, for 24 and 48 h) induced apoptosis in OCI-LY10 cells and, at concentrations of 0.03-3 μM, inhibited IRAK4 phosphorylation and associated signaling pathways. Furthermore, IRAK4-IN-27 (0.1 μM and 0.2 μM, 48 h) in combination with Ibrutinib suppressed OCI-LY10 cell growth and induced apoptosis. [1] |
Molecular Weight | 430.46 |
Formula | C23H22N6O3 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.